Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Stimulator of interferon genes agonists attenuate type I diabetes progression in NOD mice.

Lemos H, Mohamed E, Huang L, Chandler PR, Ou R, Pacholczyk R, Mellor AL.

Immunology. 2019 Dec;158(4):353-361. doi: 10.1111/imm.13122. Epub 2019 Oct 15.

PMID:
31557322
2.

Activation of the STING adaptor attenuates experimental autoimmune encephalitis.

Lemos H, Huang L, Chandler PR, Mohamed E, Souza GR, Li L, Pacholczyk G, Barber GN, Hayakawa Y, Munn DH, Mellor AL.

J Immunol. 2014 Jun 15;192(12):5571-8. doi: 10.4049/jimmunol.1303258. Epub 2014 May 5.

3.

Cutting edge: DNA sensing via the STING adaptor in myeloid dendritic cells induces potent tolerogenic responses.

Huang L, Li L, Lemos H, Chandler PR, Pacholczyk G, Baban B, Barber GN, Hayakawa Y, McGaha TL, Ravishankar B, Munn DH, Mellor AL.

J Immunol. 2013 Oct 1;191(7):3509-13. doi: 10.4049/jimmunol.1301419. Epub 2013 Aug 28.

4.

Engineering DNA nanoparticles as immunomodulatory reagents that activate regulatory T cells.

Huang L, Lemos HP, Li L, Li M, Chandler PR, Baban B, McGaha TL, Ravishankar B, Lee JR, Munn DH, Mellor AL.

J Immunol. 2012 May 15;188(10):4913-20. doi: 10.4049/jimmunol.1103668. Epub 2012 Apr 18.

5.

Physiologic control of IDO competence in splenic dendritic cells.

Baban B, Chandler PR, Johnson BA 3rd, Huang L, Li M, Sharpe ML, Francisco LM, Sharpe AH, Blazar BR, Munn DH, Mellor AL.

J Immunol. 2011 Sep 1;187(5):2329-35. doi: 10.4049/jimmunol.1100276. Epub 2011 Aug 3.

6.

Leishmania major attenuates host immunity by stimulating local indoleamine 2,3-dioxygenase expression.

Makala LH, Baban B, Lemos H, El-Awady AR, Chandler PR, Hou DY, Munn DH, Mellor AL.

J Infect Dis. 2011 Mar 1;203(5):715-25. doi: 10.1093/infdis/jiq095. Epub 2011 Jan 31.

7.

Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice.

Sharma MD, Hou DY, Baban B, Koni PA, He Y, Chandler PR, Blazar BR, Mellor AL, Munn DH.

Immunity. 2010 Dec 14;33(6):942-54. doi: 10.1016/j.immuni.2010.11.022. Epub 2010 Dec 9.

8.

B-lymphoid cells with attributes of dendritic cells regulate T cells via indoleamine 2,3-dioxygenase.

Johnson BA 3rd, Kahler DJ, Baban B, Chandler PR, Kang B, Shimoda M, Koni PA, Pihkala J, Vilagos B, Busslinger M, Munn DH, Mellor AL.

Proc Natl Acad Sci U S A. 2010 Jun 8;107(23):10644-8. doi: 10.1073/pnas.0914347107. Epub 2010 May 24.

9.

IDO activates regulatory T cells and blocks their conversion into Th17-like T cells.

Baban B, Chandler PR, Sharma MD, Pihkala J, Koni PA, Munn DH, Mellor AL.

J Immunol. 2009 Aug 15;183(4):2475-83. doi: 10.4049/jimmunol.0900986. Epub 2009 Jul 27.

10.

Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase.

Muller AJ, Sharma MD, Chandler PR, Duhadaway JB, Everhart ME, Johnson BA 3rd, Kahler DJ, Pihkala J, Soler AP, Munn DH, Prendergast GC, Mellor AL.

Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17073-8. doi: 10.1073/pnas.0806173105. Epub 2008 Oct 24.

11.

Role of CD28 in fatal autoimmune disorder in scurfy mice.

Singh N, Chandler PR, Seki Y, Baban B, Takezaki M, Kahler DJ, Munn DH, Larsen CP, Mellor AL, Iwashima M.

Blood. 2007 Aug 15;110(4):1199-206. Epub 2007 Apr 26.

12.

Cell-autonomous control of interferon type I expression by indoleamine 2,3-dioxygenase in regulatory CD19+ dendritic cells.

Manlapat AK, Kahler DJ, Chandler PR, Munn DH, Mellor AL.

Eur J Immunol. 2007 Apr;37(4):1064-71.

13.

Enrichment of regulatory CD4(+)CD25(+) T cells by inhibition of phospholipase D signaling.

Singh N, Seki Y, Takami M, Baban B, Chandler PR, Khosravi D, Zheng X, Takezaki M, Lee JR, Mellor AL, Bollag WB, Iwashima M.

Nat Methods. 2006 Aug;3(8):629-36.

PMID:
16862138
15.

A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation.

Baban B, Hansen AM, Chandler PR, Manlapat A, Bingaman A, Kahler DJ, Munn DH, Mellor AL.

Int Immunol. 2005 Jul;17(7):909-19. Epub 2005 Jun 20.

PMID:
15967784
16.

Why do some females reject males? The molecular basis for male-specific graft rejection.

Scott DM, Ehrmann IE, Ellis PS, Chandler PR, Simpson E.

J Mol Med (Berl). 1997 Feb;75(2):103-14. Review.

PMID:
9083928
17.

Acceptance of skin grafts between mice bearing different allelic forms of beta 2-microglobulin.

Hederer RA, Chandler PR, Dyson PJ, Antoniou AN, Millrain MM, Mellor AL, Simpson E, Robinson PJ.

Transplantation. 1996 Jan 27;61(2):299-304.

PMID:
8600640
18.

Expression of major histocompatibility complex class I antigens at low levels in the thymus induces T cell tolerance via a non-deletional mechanism.

Husbands SD, Schönrich G, Arnold B, Chandler PR, Simpson E, Philpott KL, Tomlinson P, O'Reilly L, Cooke A, Mellor AL.

Eur J Immunol. 1992 Oct;22(10):2655-61.

PMID:
1396970
19.

Anti-H-Y responses of H-2b mutant mice.

Simpson E, Gordon RD, Chandler PR, Bailey D.

Eur J Immunol. 1978 Oct;8(10):685-7.

PMID:
101378
20.

Cytotoxic T-cell responses to H-Y: correlation with the rejection of syngeneic male skin grafts.

Hurme M, Chandler PR, Hetherington CM, Simpson E.

J Exp Med. 1978 Mar 1;147(3):768-75.

21.

Cytotoxic T-cell responses to H-Y: mapping of the Ir genes.

Hurme M, Hetherington CM, Chandler PR, Simpson E.

J Exp Med. 1978 Mar 1;147(3):758-67.

Supplemental Content

Loading ...
Support Center